Stock ALPRE PREDILIFE
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

PREDILIFE Share Price Euronext Paris

Equities

ALPRE

FR0010169920

Biotechnology & Medical Research

End-of-day quote Euronext Paris
Other stock markets
- - Intraday chart for PREDILIFE
2023 Predilife: a project accredited by Finance Innovation CF
2023 Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Financials

Sales 2022 289K 309K 0 25.74M Sales 2023 * - Capitalization 18.87M 20.18M 0 1.68B
Net income 2022 * - Net income 2023 * - EV / Sales 2022 79.4 x
Net cash position 2022 3.52M 3.76M 0 314M Net cash position 2023 * - 0 - 0 EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees -
Yield 2022 *
-
Yield 2023 *
-
Free-Float 94.11%
More Fundamentals * Assessed data

Latest news about PREDILIFE

Predilife: a project accredited by Finance Innovation CF
Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Predilife: predictive assessment contract with Colas CF
Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Predilife Taps Eurofins to Conduct Genetic Testing of Saliva Samples MT
Global markets live: Valneva, Glencore, Facebook, Roche, Hertz... Our Logo
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Global markets live: Valneva,Boeing, Facebook, Kubota, Otis... Our Logo
Global markets live: Credit Suisse, Apple, Verizon... Our Logo
Predilife S.A. and Institut Curie Announce Partnership Covering Genetic Analyses for Mammorisk, the Next-Generation Test Predicting the Risk of Breast Cancer CI
Predilife S.A. has completed an IPO in the amount of €3.591232 million. CI
Predilife S.A. has filed an IPO in the amount of €7.006296 million. CI
More news

Press releases PREDILIFE

Predilife : Valuation of MammoRisk(R) software AT
PrediLife : and the Institut Curie Announce a Partnership Covering Genetic Analyses for MammoRisk®, the Next-Generation Test Predicting the Risk of Breast Cancer BU
More press releases

News in other languages on PREDILIFE

Predilife : Valorisation du logiciel MammoRisk(R)
Predilife : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2023
Predilife : en hausse après la progression de son activité en 2023
Predilife : RÉSULTATS ANNUELS 2023 - PROGRESSION DES VENTES AUX ENTREPRISES ET SUCCÈS DU RECRUTEMENT DES PATIENTES DANS L’ÉTUDE CLINIQUE EUROPÉENNE
Predilife : RÉSULTATS DE L’ÉTUDE IPSOS PORTANT SUR LA SANTE ET LE BIEN-ÊTRE DES SALARIÉS : 79% DES SALARIÉS INTÉRESSÉS PAR LE BILAN PRÉDICTIF DE PREDILIFE
More news

Managers and Directors - PREDILIFE

Managers TitleAgeSince
Stéphane Ragusa CEO
 Chief Executive Officer 53 01/04/01
Émilien Gauthier CTO
 Chief Tech/Sci/R&D Officer - 01/07/01
Marion Renelier LAW
 General Counsel - 01/16/01
Members of the board TitleAgeSince
Charles Vilgrain BRD
 Director/Board Member 44 01/18/01
Stéphane Ragusa CEO
 Chief Executive Officer 53 01/04/01
Antoine Bricard BRD
 Director/Board Member 56 01/18/01
More insiders

Company Profile

PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women and over 300,000 French women.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Diagnostics & Testing

1st Jan change Capi.
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 383M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. ALPRE Stock
  4. ALPRE Stock